NYC, San Francisco and other US cities capping LGBTQ+ Pride month with a mix of party and protest
The festivities in Manhattan, home to the nation's oldest and largest Pride celebration, kick off with a march down Fifth Avenue featuring more than 700 participating groups and huge crowds are expected.
Marchers will wind past the Stonewall Inn, a Greenwich Village gay bar where a 1969 police raid triggered protests and fired up the LGBTQ+ rights movement. The site is now a national monument.
In San Francisco, marchers in another of the world's largest Pride events will head down the city's central Market Street, reaching concert stages set up at the Civic Center Plaza. San Francisco's mammoth City Hall is also among the venues hosting a post-march party.
Chicago, Seattle, Minneapolis and Toronto, Canada, are among the other major North American cities hosting Pride parades on Sunday.
Several global cities, including Tokyo, Paris and Sao Paulo, held their events earlier this month, while others come later in the year, including London in July and Rio de Janeiro in November.
The first Pride march was held in New York City in 1970 to commemorate the one-year anniversary of the Stonewall uprising.
Pride celebrations are typically a daylong mix of jubilant street parties and political protest, but organizers said this year's iterations will take a more defiant stance than recent years.
The festivities come days after the tenth anniversary of the Supreme Court's landmark June 26, 2015, ruling in Obergefell v. Hodges that recognized same-sex marriage nationwide.
But Republicans, led by President Donald Trump, have sought to roll back LGBTQ+ friendly policies.
Since taking office in January, Trump has specifically targeted transgender people, removing them from the military, preventing federal insurance programs from paying for gender-affirmation surgeries for young people and attempting to keep transgender athletes out of girls' and women's sports.
The theme for the Manhattan event is, appropriately, 'Rise Up: Pride in Protest.' San Francisco's Pride theme is 'Queer Joy is Resistance' while Seattle's is simply 'Louder.'
'This is not a time to be quiet,' Patti Hearn, Seattle Pride's executive director, said in a statement ahead of the event. 'We will stand up. We will speak up. We will get loud.'
Among the other headwinds faced by gay rights groups this year is the loss of corporate sponsorship.
American companies have pulled back support of Pride events, reflecting a broader walking back of diversity and inclusion efforts amid shifting public sentiment.
NYC Pride said earlier this month that about 20% of its corporate sponsors dropped or reduced support, including PepsiCo and Nissan. Organizers of San Francisco Pride said they lost the support of five major corporate donors, including Comcast and Anheuser-Busch.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Trump Says JPMorgan, Bank of America Refused His Business
(Bloomberg) -- President Donald Trump accused two of the nation's largest banks of rejecting his business, following as his administration was preparing an executive order threatening financial institutions who refused to work with certain customers on ideological grounds. PATH Train Service Resumes After Fire at Jersey City Station Mayor Asked to Explain $1.4 Billion of Wasted Johannesburg Funds Chicago Curbs Hiring, Travel to Tackle $1 Billion Budget Hole All Hail the Humble Speed Hump 'The banks discriminated against me very badly,' Trump said in an interview Tuesday with CNBC. Trump said he had been 'informed by my people' that JPMorgan Chase & Co. had asked him to close accounts he held for decades within 20 days, and that Bank of America Corp. declined his attempt to deposit more than $1 billion with their company. 'I ended up going to small banks all over the place,' Trump said. The president added that he believed banking regulators during the Biden administration had been ordered to 'do everything you can to destroy Trump, and that's what they did.' 'Banks are not afraid of anything but a regulator — their regulators and their wives,' Trump said. He didn't offer exact dates for his dealings with JPMorgan and Bank of America, though he suggested the latter occurred between his two presidential terms. The defeat in New York's civil fraud suit against Trump and his real estate company last year put restrictions on his ability to do business in the state. That included a three-year ban on the Trump Organization getting loans from New York-chartered banks. Trump has asked a Manhattan appeals court to overturn the civil fraud verdict. Trump was asked on Tuesday about a Wall Street Journal report that his administration was drafting an order that would direct bank regulators to investigate whether any financial institutions might have violated federal laws in closing certain accounts. Any direction from the White House would require both banks and regulators to review and submit their findings of how they engage with their customers. In the draft of the executive order being circulated among industry participants, banks would undergo a 120-day review process of their rationale for closing customer accounts, the people familiar with the matter said. Financial regulators would also undergo their own review process, between 120 and 180 days, to examine how they regulate and impose restrictions on banks that could lead to account closures, the people said, asking not to be identified discussing nonpublic information. The order also would call for any criminal findings that come from the review process to be submitted directly to the Department of Justice, said the people. A final executive order is expected to be submitted at some point this week, though timing and the material itself could change, they added. A representative for the White House did not immediately respond to a request for comment. Both JPMorgan and Bank of America have previously denied rejecting business on ideological grounds. 'Desperately Needed' 'We don't close accounts for political reasons, and we agree with President Trump that regulatory change is desperately needed,' Trish Wexler, a JPMorgan spokesperson, said in a statement. 'We commend the White House for addressing this issue and look forward to working with them to get this right.' 'We welcome the Trump administration's efforts to provide regulatory clarity to banks,' Bank of America spokesperson William Halldin said in a statement. 'We've provided detailed proposals and will continue to work with the administration and Congress to improve the regulatory framework.' The Bank Policy Institute also said rules need to be reworked. 'The heart of the problem is regulatory overreach and supervisory discretion,' Austin Anton, a Bank Policy Institute spokesperson, said Tuesday. 'The banking agencies have already taken steps to address issues like reputational risk, and we're hopeful that any forthcoming executive order will reinforce this progress by directing regulators to confront the flawed regulatory framework that gave rise to these concerns in the first place.' Federal banking regulators have said they'll remove reputation risk from their bank exams, aiming to eliminate a factor that lenders have blamed for forcing them to exit some client relationships. Conservatives have complained that major Wall Street firms have debanked gunmakers, fossil-fuel companies, religious groups and cryptocurrency firms. Trump aired that complaint to Bank of America Chief Executive Officer Brian Moynihan directly during a panel at the World Economic Forum in Davos earlier this year. 'We serve more than 70 million clients and we welcome conservatives. We are required to follow extensive government rules and regulations that sometimes result in decisions to exit client relationships,' a representative for Bank of America said in an emailed statement at the time. 'We never close accounts for political reasons and don't have a political litmus test.' Bank of America, the second-largest US bank, had restricted lending to companies that make assault-style guns used for non-military purposes, following shootings at a high school in Florida early in 2018. Citigroup Inc. also announced its own set of restrictions for clients selling guns that year. In June, Citigroup ended a seven-year policy that placed restrictions on firearms sales by its retail sector clients, citing recent legislative developments and concerns over access to banking services. The Trump Organization sued Capital One Financial Corp. in March, accusing it of closing hundreds of the real estate company's accounts in 2021 for political reasons. The president's company claims the bank ended the decades-old relationship 'simply because Capital One believed that the political views at the time favored doing so.' In a setback for Trump's company, a federal judge in July granted Capital One's request to delay the exchange of evidence in the case until after the bank's motion to dismiss is resolved. Capital One argues its agreements with the Trump Organization allowed it to close its accounts for any reason and that it gave the business plenty of advanced notice. The bank also says Trump's company has failed to provide any evidence that the accounts were closed for political purposes. Earlier this year JPMorgan Chase & Co.'s Jamie Dimon on Capitol Hill offered his support to a restructuring of US financial regulators. Bank of America went on to loosen its gun restrictions and made similar changes to its energy-lending policies, including dropping a blanket ban on financing for Arctic drilling, according to an environmental and social risk policy from late 2023. The issue of debanking customers has come up outside of the US as well. In the UK, it prompted an outcry a few years ago, when right-wing politician Nigel Farage — who now leads the Reform UK party — revealed NatWest Group Plc's upmarket Coutts unit had closed his account, saying his political views were a factor in that decision. The subsequent row led to the resignation of the bosses of NatWest and Coutts, while Farage had vowed to campaign for others who were been 'debanked' on questionable grounds. A preliminary review by the UK's Financial Conduct Authority found no evidence that banks were dropping customers for their political opinion. --With assistance from Hannah Levitt, Erik Larson and Hadriana Lowenkron. (Updates with details on draft executive order in paragraphs 10-13) Russia's Secret War and the Plot to Kill a German CEO AI Flight Pricing Can Push Travelers to the Limit of Their Ability to Pay Government Steps Up Campaign Against Business School Diversity What Happens to AI Startups When Their Founders Jump Ship for Big Tech How Podcast-Obsessed Tech Investors Made a New Media Industry ©2025 Bloomberg L.P.
Yahoo
an hour ago
- Yahoo
Pfizer Lifts Profit View as Cuts Offset Flat Sales Outlook
(Bloomberg) -- Pfizer Inc. raised its profit forecast for the year, with the drugmaker's ongoing cost cuts helping to make up for a lack of expected sales growth. PATH Train Service Resumes After Fire at Jersey City Station Mayor Asked to Explain $1.4 Billion of Wasted Johannesburg Funds Chicago Curbs Hiring, Travel to Tackle $1 Billion Budget Hole All Hail the Humble Speed Hump The company's stock rose as much as 5.4% in New York Tuesday as investors look for good news after a decline in demand for the company's Covid products forced the drugmaker to reshape its business. Adjusted profits will be between $2.90 to $3.10 per share in 2025, the New York-based company said in a statement, an increase of 10 cents per share over its prior projection. The company maintained its sales expectations of $61 billion to $64 billion, the midpoint of which would represent a decline in sales from 2024. 'It's marginally positive,' Mizuho analyst Jared Holz said. 'And with the pharmaceutical industry the toughest it's been in a long time, that's good enough.' Pfizer is in the process of rebuilding in the aftermath of the pandemic, slashing about $7.2 billion from its spending and betting on an unproven pipeline of new medicines to make up for the stagnant sales of its aging products. Adding to the pressure on Pfizer, the entire pharmaceutical industry faces the threat of sector-specific tariffs and policies that would restrict what they can charge for medicines in the US. As Pfizer was reporting its second-quarter earnings on Tuesday, President Donald Trump said in a television interview pharma tariffs would be announced 'within the next week or so.' On Thursday, Trump also sent letters to 17 of the largest drugmakers, demanding they slash the price of medicines for US customers. Pfizer Chief Executive Albert Bourla was one of the executives to have received a personal letter from the president. Pfizer has held 'productive discussions' with Trump and his administration since then, Bourla said on a conference call with analysts Tuesday, adding he has spoken up for industry priorities including reining in pharmaceutical middlemen and making changes to a Joe Biden-era law that allows the government to negotiate certain drug prices. Bourla declined to provide further details but noted he and Trump have 'a special relationship from the times of Covid,' when Pfizer worked with the administration to develop its vaccine. 'There is no scenario that we have not assessed,' Bourla said of potential tariffs and pricing restrictions. 'There is no scenario that we have not built mitigation plans for.' In its earnings report, the company said its new guidance accounts for existing tariffs on imports from China, Canada and Mexico. Pfizer has also factored in 'potential price changes this year' that may result from Trump's demands. Pfizer's relies on a global network of manufacturing sites to supply its drugs. Profit Projection The drugmaker attributed its increased 2025 profit projection to its ongoing cost cuts, the effects of the weakening dollar, and an improvement in its tax rate. The company's second-quarter sales were $14.7 billion, beating average estimates by more than $1 billion. Pfizer's biggest drug, the more than decade-old blood thinner Eliquis, surpassed expectations and the pneumonia vaccine Prevnar beat the Street's view. Sales of the company's vaccine and pill for Covid came in well above estimates. Demand for those products has precipitously declined since 2022. Pfizer faces a roughly $15 billion patent cliff by the end of the decade, and investors remain skeptical its pipeline of new medicines can eventually replace the lost revenue. The recent failure of Pfizer's weight-loss pill, the company's best shot at competing with Eli Lilly & Co. and Novo Nordisk A/S in the burgeoning obesity market, only amplified the pressure on management. Trump's health secretary Robert F. Kennedy Jr., has raised doubts about the safety of vaccines, creating other risks for Pfizer, which counts on its shots for Covid, RSV, and pneumonia for nearly 20% of sales. (Updates throughout.) Russia's Secret War and the Plot to Kill a German CEO AI Flight Pricing Can Push Travelers to the Limit of Their Ability to Pay Government Steps Up Campaign Against Business School Diversity What Happens to AI Startups When Their Founders Jump Ship for Big Tech How Podcast-Obsessed Tech Investors Made a New Media Industry ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Politico
an hour ago
- Politico
Will feds weigh in on religious vax carveouts?
Driving the Day RELIGIOUS VAX EXEMPTIONS — It's back-to-school season, which means parents are shuttling their kids to pediatricians for annual checkups — and advocates for and against states' exemptions to vaccine mandates for school entry are gearing up for a fight, Lauren reports. Vaccine skeptics have sought to make their case to the Trump administration's Religious Liberty Commission — created by executive order in May — for executive action to bolster religious carve-outs. But they face pushback from public health experts who warn that more exemptions could threaten public health, setting up another front in the vaccine wars. Four states — California, Connecticut, Maine and New York — don't offer religious exemptions to school vaccine requirements, and Massachusetts lawmakers are considering banning them. West Virginia provides exemptions after GOP Gov. Patrick Morrisey signed an executive order earlier this year invoking the state's religious freedom law. Some religious liberty groups have called on the federal government — which has no say in state vaccine mandates — to use federal education funding as leverage to expand religious opt-outs from school immunization requirements, pointing to a Clinton-era religious protection statute. Precedential web: Some vaccine law experts question how far the executive branch could go to nudge those outlier states toward accepting religious exemptions. The Supreme Court curtailed the Religious Freedom Restoration Act's application to the states in 1997, and administrative conditions on federal funding can't run afoul of Congress' directions. But proponents say those lawyers ignore more recent opinions that work in exemption advocates' favor, pointing to a Covid-19-era decision lifting in-home gathering restrictions on religious grounds and, more recently, the court's ruling in favor of parents who want to opt their children out of LGBTQ+-themed lessons in public schools. Shifting winds: The number of kindergarteners entering school with at least one vaccine exemption continues to tick up, with the CDC reporting last week that 3.6 percent had one in the 2024-2025 school year, compared with 2.2 percent a decade ago. Days before the updated data was released, the American Academy of Pediatrics reaffirmed its opposition to religious exemptions, arguing they should be abolished to protect public health. 'In practice, nonmedical exceptions based on religious belief can substantially limit the public health value of vaccine requirements for school attendance,' the group said in a statement. 'There is no practicable way for schools or other involved community partners to distinguish fairly among religious or other nonmedical claims.' What's next: The Religious Liberty Commission will hold a hearing next month on public education issues, giving exemption proponents another opening to make their case. It's unclear where the White House stands on the concept — a spokesperson didn't comment — but the first Trump administration's HHS pursued avenues to grant health care workers expanded 'conscience' protections and to allow imports of certain vaccines due to some patients' religious beliefs. IT'S TUESDAY. WELCOME BACK TO PRESCRIPTION PULSE. Your host is wondering whether concerns about a common allergy medicine's risks might catch the FDA's attention. Send tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). Eye on the FDA NEW TOP LAWYER — FDA Commissioner Marty Makary named a longtime government attorney on Monday to be the agency's chief counsel, months after his first pick was torpedoed by Sen. Josh Hawley (R-Mo.). Sean Keveney, who most recently served as HHS's acting general counsel, served as a career civil servant at DOJ's civil rights division before becoming deputy general counsel at HHS in 2019, according to the department and his LinkedIn profile. His predecessor in the position, Hilary Perkins, was also a career DOJ lawyer whose appointment drew Hawley's ire before Makary's confirmation because of her record defending the Biden administration's abortion pill policies. While Perkins also defended the Trump FDA's mifepristone positions, that wasn't enough to overcome his opposition, and she ultimately stepped down days into the job. MDUFA KICKOFF — The FDA's medical device user fee program is not set to expire until Sept. 30, 2027, but the process to renew it has already begun. Despite HHS Secretary Robert F. Kennedy Jr.'s vocal distaste for the user fee programs, the Trump administration has made it clear they are committed to the monthslong process that will likely result in their renewal for another five years. Industry and FDA leaders — including FDA Commissioner Marty Makary and Center for Devices and Radiological Health Director Michelle Tarver — met Monday to discuss the potential sixth iteration of the medical device user fee program. 'While user fees support timeliness and predictability by providing FDA with additional resources, user fees are not a guarantee of approval,' AdvaMed's senior executive vice president, Janet Trunzo, said according to prepared remarks. 'They never have been, and they never should be.' In Congress SENATE PASSES FDA FUNDING — Before leaving town for the August recess, the Senate passed a bill to fund the FDA for fiscal 2026 as part of a minibus package by an 87-9 vote. The legislation, which funds the agency at $7 billion, is made up of $3.6 billion in taxpayer funds and $3.4 billion in user fee revenues. But it is unclear whether lawmakers will have to turn to a continuing resolution before government funding runs out at the end of September. The House Appropriations Committee previously advanced an FDA bill that funded the agency at a lower level. Research Corner BOOST FOR WOMEN'S HEALTH — The Gates Foundation said Monday it would spend $2.5 billion through 2030 to speed global women's research into maternal, menstrual, gynecological and sexual health. Pharma Moves Erika Sward is now chief advocacy officer at UsAgainstAlzheimer's. She previously was assistant vice president of national advocacy at the American Lung Association. Document Drawer FDA Commissioner Marty Makary met with Rep. John Joyce (R-Pa.) for an introductory meeting on July 24. He also met with People for the Ethical Treatment of Animals to discuss nonanimal testing approaches on July 21, according to newly posted public calendar disclosures. He also met with the leadership team of the Government Accountability Office on July 16 to discuss 'items of mutual interest.' WHAT WE'RE READING Top FDA cancer medicine regulator Richard Pazdur played a critical role in the rejection of Replimune Group's skin cancer therapy, STAT's Adam Feuerstein reports. Longevity companies are eyeing Montana as a potential hub for 'biohacking' treatments thanks to state laws embracing patients' 'right-to-try' experimental drugs, The Wall Street Journal's Alex Janin writes.
